東華大學圖書館 |

Language: English

Help

回圖書館首頁

手機版館藏查詢

Back

Switch To: Labeled | MARC Mode | ISBD

Neuroproteomics as a tool for unders...

Martins-de-Souza, Daniel.

Linked to FindBook

Google Book

Amazon

博客來

Neuroproteomics as a tool for understanding schizophrenia

Record Type:	Electronic resources : Monograph/item
Title/Author:	Neuroproteomics as a tool for understanding schizophrenia/ edited by Daniel Martins-de-Souza.
other author:	Martins-de-Souza, Daniel.
Published:	Cham :Springer International Publishing : : 2022.,
Description:	viii, 143 p. :ill. (some col.), digital ;24 cm.
[NT 15003449]:	1. Postmortem brains: what can proteomics tell us about the sources of schizophrenia? -- 2. What can we learn from animal models to study schizophrenia? -- 3. Modeling schizophrenia in vitro: challenges and insights on studying brain cell -- 4. Schizophrenia outside the brain -- 5. Molecular features triggered by antipsychotic medication in brain cells -- 6. Known and Unexplored Post-Translational Modification Pathways in Schizophrenia -- 7. Molecular findings guiding the modulation of the endocannabinoid system as a potential target to treat schizophrenia -- 8. Metabolomics: A powerful tool to understand the schizophrenia biology -- 9. Modulating specific pathways in vitro to understand the synaptic dysfunction of schizophrenia -- 10. Proteomics and schizophrenia: the evolution of a great partnership.
Contained By:	Springer Nature eBook
Subject:	Schizophrenia - Molecular aspects. -
Online resource:	https://doi.org/10.1007/978-3-030-97182-3
ISBN:	9783030971823

Neuroproteomics as a tool for understanding schizophrenia
Neuroproteomics as a tool for understanding schizophrenia[electronic resource] /edited by Daniel Martins-de-Souza. - Cham :Springer International Publishing :2022. - viii, 143 p. :ill. (some col.), digital ;24 cm. - Proteomics, metabolomics, interactomics and systems biology,v. 14002730-6224 ;. - Proteomics, metabolomics, interactomics and systems biology ;v. 1400..

1. Postmortem brains: what can proteomics tell us about the sources of schizophrenia? -- 2. What can we learn from animal models to study schizophrenia? -- 3. Modeling schizophrenia in vitro: challenges and insights on studying brain cell -- 4. Schizophrenia outside the brain -- 5. Molecular features triggered by antipsychotic medication in brain cells -- 6. Known and Unexplored Post-Translational Modification Pathways in Schizophrenia -- 7. Molecular findings guiding the modulation of the endocannabinoid system as a potential target to treat schizophrenia -- 8. Metabolomics: A powerful tool to understand the schizophrenia biology -- 9. Modulating specific pathways in vitro to understand the synaptic dysfunction of schizophrenia -- 10. Proteomics and schizophrenia: the evolution of a great partnership.

Over the past decade, neuroproteomics has shed light on the molecular features of schizophrenia by depicting biological processes involved with its establishment, maintenance and treatment. These studies have also pointed to potential biomarkers applicable to diagnosis and medication monitoring. Edited by a leader in the field of neuroproteomics with contributions from subject experts, this new volume will address recent findings and compile evidence from difference perspectives-such as human samples, animal models, pluripotent stem cell-derived in vitro pre-clinical models-and provide findings to inform the development of innovative future treatment strategies. This volume will be useful for a broad audience of researchers and professionals, including biologists, neurologists, psychiatrists, analytical chemists, and pharmacists, among others. Provides comprehensive overview on how neuroproteomics helped depicting the molecular features of schizophrenia Addresses biological processes, treatment strategies, and recent research findings associated to schizophrenia Addresses current research challenges, future strategies, and clinical applications.

ISBN: 9783030971823

Standard No.: 10.1007/978-3-030-97182-3doiSubjects--Topical Terms:

3603694
Schizophrenia
--Molecular aspects.

LC Class. No.: RC514 / .N48 2022

Dewey Class. No.: 616.898

Neuroproteomics as a tool for understanding schizophrenia
LDR:03060nmm a2200325 a 4500 001 2302922
003 DE-He213
005 20220805131058.0
007 cr nn 008maaau
008 230409s2022 sz s 0 eng d
020 $a 9783030971823 $q (electronic bk.)
020 $a 9783030971816 $q (paper)
024 7 $a 10.1007/978-3-030-97182-3 $2 doi
035 $a 978-3-030-97182-3
040 $a GP $c GP
041 0 $a eng
050 4 $a RC514 $b .N48 2022
072 7 $a PSAK $2 bicssc
072 7 $a SCI029000 $2 bisacsh
072 7 $a PSAK $2 thema
082 0 4 $a 616.898 $2 23
090 $a RC514 $b .N494 2022
245 0 0 $a Neuroproteomics as a tool for understanding schizophrenia $h [electronic resource] / $c edited by Daniel Martins-de-Souza.
260 $a Cham : $b Springer International Publishing : $b Imprint: Springer, $c 2022.
300 $a viii, 143 p. : $b ill. (some col.), digital ; $c 24 cm.
490 1 $a Proteomics, metabolomics, interactomics and systems biology, $x 2730-6224 ; $v v. 1400
505 0 $a 1. Postmortem brains: what can proteomics tell us about the sources of schizophrenia? -- 2. What can we learn from animal models to study schizophrenia? -- 3. Modeling schizophrenia in vitro: challenges and insights on studying brain cell -- 4. Schizophrenia outside the brain -- 5. Molecular features triggered by antipsychotic medication in brain cells -- 6. Known and Unexplored Post-Translational Modification Pathways in Schizophrenia -- 7. Molecular findings guiding the modulation of the endocannabinoid system as a potential target to treat schizophrenia -- 8. Metabolomics: A powerful tool to understand the schizophrenia biology -- 9. Modulating specific pathways in vitro to understand the synaptic dysfunction of schizophrenia -- 10. Proteomics and schizophrenia: the evolution of a great partnership.
520 $a Over the past decade, neuroproteomics has shed light on the molecular features of schizophrenia by depicting biological processes involved with its establishment, maintenance and treatment. These studies have also pointed to potential biomarkers applicable to diagnosis and medication monitoring. Edited by a leader in the field of neuroproteomics with contributions from subject experts, this new volume will address recent findings and compile evidence from difference perspectives-such as human samples, animal models, pluripotent stem cell-derived in vitro pre-clinical models-and provide findings to inform the development of innovative future treatment strategies. This volume will be useful for a broad audience of researchers and professionals, including biologists, neurologists, psychiatrists, analytical chemists, and pharmacists, among others. Provides comprehensive overview on how neuroproteomics helped depicting the molecular features of schizophrenia Addresses biological processes, treatment strategies, and recent research findings associated to schizophrenia Addresses current research challenges, future strategies, and clinical applications.
650 0 $a Schizophrenia $x Molecular aspects. $3 3603694
650 0 $a Schizophrenia $x Physiological aspects. $3 3603695
650 0 $a Proteomics. $3 600542
650 1 4 $a Genomics. $3 600531
650 2 4 $a Computational and Systems Biology. $3 3531279
650 2 4 $a Neuroscience. $3 917253
700 1 $a Martins-de-Souza, Daniel. $3 2152849
710 2 $a SpringerLink (Online service) $3 836513
773 0 $t Springer Nature eBook
830 0 $a Proteomics, metabolomics, interactomics and systems biology ; $v v. 1400. $3 3603693
856 4 0 $u https://doi.org/10.1007/978-3-030-97182-3
950 $a Biomedical and Life Sciences (SpringerNature-11642)